Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An Open-label, Randomised, Comparative, Multi-centre Study of the Immunogenicity and Safety of a 1-dose Regimen and Different 2-dose Regimens of a Zoster Vaccine (Live), ZOSTAVAX ®, in Subjects ≥ 70 Years of Age
Brief Summary: Primary objective:

Immunogenicity To demonstrate that a second dose of ZOSTAVAX® elicits higher varicella-zoster virus (VZV) antibody titres than a first dose of ZOSTAVAX® whether given as a 0-1 month schedule or as a 0-3 month schedule in subjects ≥70 years of age as measured at 4 weeks post-vaccination

Secondary objectives Immunogenicity

* To summarise the VZV antibody titres at 4 weeks post-vaccination after a 1-dose regimen and 4 weeks post-vaccination after each dose of each 2-doses regimen of ZOSTAVAX®.
* To compare the VZV antibody titres at 12 months after completion of a 1-dose regimen with the VZV antibody titres at 12 months after completion of each 2-doses regimen of ZOSTAVAX®
* To summarise the VZV antibody titres at 24 and 36 months after completion of a 1-dose regimen and at 24 and 36 months after completion of each 2-doses regimen of ZOSTAVAX®


Options:
A: Arm Label: HZ/su Lot A; Type: EXPERIMENTAL; Interventions: Biological: Herpes Zoster vaccine (GSK 1437173A) | Arm Label: HZ/su Lot B; Type: EXPERIMENTAL; Interventions: Biological: Herpes Zoster vaccine (GSK 1437173A) | Arm Label: HZ/su Lot C; Type: EXPERIMENTAL; Interventions: Biological: Herpes Zoster vaccine (GSK 1437173A) | Intervention Type: BIOLOGICAL; Name: Herpes Zoster vaccine (GSK 1437173A); Assigned to Arm(s): HZ/su Lot A, HZ/su Lot B, HZ/su Lot C
B: Arm Label: Zoster vaccine group; Type: EXPERIMENTAL; Interventions: Biological: Herpes Zoster Vaccine GSK1437173A | Arm Label: Placebo group; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Intervention Type: BIOLOGICAL; Name: Herpes Zoster Vaccine GSK1437173A; Assigned to Arm(s): Zoster vaccine group | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo group
C: Arm Label: Co-Ad Group; Type: EXPERIMENTAL; Interventions: Biological: Herpes Zoster vaccine GSK 1437173A, Biological: Licensed pneumococcal polysaccharide conjugate vaccine (23-valent, adsorbed), Pneumovax 23™ | Arm Label: Control Group; Type: ACTIVE_COMPARATOR; Interventions: Biological: Herpes Zoster vaccine GSK 1437173A, Biological: Licensed pneumococcal polysaccharide conjugate vaccine (23-valent, adsorbed), Pneumovax 23™ | Intervention Type: BIOLOGICAL; Name: Herpes Zoster vaccine GSK 1437173A; Assigned to Arm(s): Co-Ad Group, Control Group | Intervention Type: BIOLOGICAL; Name: Licensed pneumococcal polysaccharide conjugate vaccine (23-valent, adsorbed), Pneumovax 23™; Assigned to Arm(s): Co-Ad Group, Control Group
D: Arm Label: Single Dose of Zostavax; Type: EXPERIMENTAL; Interventions: Biological: Zostavax | Arm Label: Zostavax - Day 0 and Month 1; Type: EXPERIMENTAL; Interventions: Biological: Zostavax | Arm Label: Zostavax - Day 0 and Month 3; Type: EXPERIMENTAL; Interventions: Biological: Zostavax | Intervention Type: BIOLOGICAL; Name: Zostavax; Assigned to Arm(s): Single Dose of Zostavax, Zostavax - Day 0 and Month 1, Zostavax - Day 0 and Month 3

Answer: D